Default company panoramic image

Aria Neurosciences, Inc.

Aria is a biotechnology company dedicated to developing disease-modifying drugs to treat patients with Alzheimer’s disease.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Hamden, CT, USA
  • Currency USD
  • Website

Company Summary

Aria Neurosciences, Inc. is a biopharmaceutical company focusing on discovery, development and commercialization of disease modifying small molecule therapeutics to treat diseases of protein aggregation including Alzheimer's disease and related disorders.


  • Default avatar
    Bijan Almassian
    President & CEO

    Dr. Almassian has over 20 years of experience in the pharmaceutical industry across multiple disciplines including Research & Development, Strategic Planning, Business Development and Operations Management. He is currently the Founder and President of Pars Pharmaceutical Consulting, providing overall drug development and regulatory expertise to pharmaceutical and biotechnology companies. Prior to Pars, he served as President and CEO of ExSAR Corp

  • Default avatar
    George Perry
    Chairman of the Scientific Advisory Board

    George Perry, Ph.D. is Dean of the College of Sciences and Professor of Biology at The University of Texas at San Antonio. Dr. Perry is recognized in the field of Alzheimer's disease research, particularly for his work on oxidative stress. Dr. Perry received his Bachelor of Arts degree in zoology with high honors from University of California, Santa Barbara. After graduation, he headed to Scripps Institute of Oceanography and obtained his Ph.D

  • Default avatar
    David Palling
    Senior Pharmaceutical Development Advisor

    David Palling, Ph.D. has worked in the pharmaceutical industry for over 25 years and has broad experience in the Preclinical, Early Clinical, and CMC aspects of Drug Development. Most recently, he was the Senior Vice President for Technical Operations at Amicus Therapeutics, a clinical stage company located in New Jersey. Prior to that position, while also at Amicus Therapeutics, he was the Senior Vice President for Preclinical Development. Dr

  • Default avatar
    Peggy Harbison
    Senior Vice President Preclinical Development

    Dr. Harbison has had 20 years experience in drug and companion diagnostics development at Roche with particular expertise in project leadership, clinical and regulatory strategies, and preclinical drug development. Most recently, she was Vice President at Roche Molecular Diagnostics where she was responsible for a development portfolio of molecular biomarker and companion diagnostics in the Genomics and Oncology business area. Prior to that, Dr.